Advertisement

Complementary and Alternative Medicine for Painful Peripheral Neuropathy

  • Vanessa BauteEmail author
  • Danielle Zelnik
  • Jarret Curtis
  • Fatemeh Sadeghifar
Neuromuscular Disorders (C Fournier, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuromuscular Disorders

Abstract

Purpose of review

The purpose of our manuscript is to review the current evidence supporting the use of complementary and alternative medicine (CAM) in neuromuscular disease, specifically in painful peripheral neuropathy (PPN). We outline the therapeutic challenges of this debilitating condition and describe the best evidence for incorporating such therapies into clinical practice. The most studied modalities include lifestyle modifications with diet and exercise, supplements, and acupuncture. CAM therapies such as yoga, meditation, electrical stimulation, neuromodulatory devices, and cannabis are mentioned as emerging therapies.

Recent findings

Current data suggests that targeted lifestyle modifications, including aerobic exercise and diet modifications that promote weight loss, may improve the natural course of diabetic painful neuropathy and potentially other types of neuropathy. A number of studied dietary supplements and vitamins including B vitamins, vitamin D, alpha-lipoic acid, and acetyl-l-carnitine improve both subjective and objective neuropathic measures. A wide range of neuromodulatory devices and electrical stimulation modalities demonstrate mixed results, and further studies are needed to confirm their benefit. Finally, acupuncture and yoga both demonstrate benefit in a variety of PPNs.

Summary

Multiple CAM therapies show efficacy in the treatment of PPN. From the strongest level of evidence to the least, lifestyle modifications including exercise and diet; supplements including B12, alpha lipoic acid, acetyl-l-carnitine, and vitamin D in deficient patients; followed by acupuncture and yoga may alleviate symptoms of PPN.

Keywords

Diabetic neuropathy Alternative therapies Neuropathy treatment Peripheral neuropathy Neuromodulation 

Notes

Acknowledgments

The authors would like to thank Ms. Indra Maria Newman for her editing support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Rutkove S, Shefner JM, Eichler AF. Overview of polyneuropathy. UpToDate. 2018.Google Scholar
  2. 2.
    Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: differential diagnosis and management. Am Fam Physician. 2010;81(7):887–92.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med. 2009;10(5):918–29.  https://doi.org/10.1111/j.1526-4637.2009.00655.x.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Feldman EL, Shefner JM, Dashe JF. Epidemiology and classification of diabetic neuropathy. UpToDate. 2013.  https://doi.org/10.1017/CBO9781107415324.004.
  5. 5.
    Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(Suppl 2):S50–62.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518–22.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Puplampu P, Ganu V, Kenu E, Kudzi W, Adjei P, Grize L, et al. Peripheral neuropathy in patients with human immunodeficiency viral infection at a tertiary hospital in Ghana. J NeuroVirol. 2019.  https://doi.org/10.1007/s13365-019-00743-0.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Javed S, Alam U, Malik RA. Treating diabetic neuropathy: present strategies and emerging solutions. Rev Diabet Stud. 2015;12(1–2):63–83.  https://doi.org/10.1900/RDS.2015.12.63.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tavakoli M, Asghar O, Alam U, Petropoulos IN, Fadavi H, Malik RA. Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy. Ther Adv Endocrinol Metab. 2010;1(2):69–88.  https://doi.org/10.1177/2042018810370954.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    •• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(S1):35–42.  https://doi.org/10.1007/s40122-017-0087-0. This paper provides a comprehensive groundwork for the difficulties and history of treatment of neuropathic pain in clinical practice.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.  https://doi.org/10.1016/S1474-4422(14)70251-0.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Abbott RB, Hui K-K, Hays RD, Mandel J, Goldstein M, Winegarden B, et al. Medical student attitudes toward complementary, alternative and integrative medicine evidence-based complementary and alternative medicine. 2011;2011:1–14.  https://doi.org/10.1093/ecam/nep195.CrossRefGoogle Scholar
  13. 13.
    Colloca L, Ludman T, Bouhassira D, et al. HHS Public Access. 2017;(Imi).  https://doi.org/10.1038/nrdp.2017.2.Neuropathic.
  14. 14.
    Hehn V, Christian A, et al. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638–52.  https://doi.org/10.1016/j.neuron.2012.02.008.CrossRefGoogle Scholar
  15. 15.
    Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361–8.CrossRefGoogle Scholar
  16. 16.
    Yoo M, D’Silva LJ, Martin K, Sharma NK, Pasnoor M, LeMaster JW, et al. Pilot study of exercise therapy on painful diabetic peripheral neuropathy. Pain Med. 16(8):1482–9.  https://doi.org/10.1111/pme.12743.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    •• Dixit D, Maiya A, Shastry BA. Effects of aerobic exercise of vibration perception threshold in type 2 diabetic peripheral neuropathy using 3-sites method: single-blind randomized controlled trial. Altern Ther Health Med. 2019;25(2):36–41 This randomized trial outlines the effect of incorporating exercise into the treatment regimen of diabetics with neuropathic pain on their sensory exam.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Tofthagen VC, Berry DL. Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum. 2012;39(5):E416–24.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.  https://doi.org/10.1007/s11892-014-0528-7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bunner AE, Wells CL, Gonzales J, Agarwal U, Bayat E, Barnard ND. A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study. Nutr Diabetes. 2015;5:e158.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Ghavami H, Radfar M, Soheily S, Shamsi SA, Khalkhali HR. Effect of lifestyle interventions on diabetic peripheral neuropathy in patients with type 2 diabetes, result of a randomized controlled trial. Agri. 2018;30(4):165–70.  https://doi.org/10.5505/agri.2018.45477.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Look AHEAD Research Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Diabetologia. 2017;60(6):980–8.  https://doi.org/10.1007/s00125-017-4253-z. This trial highlights the importance of lifestyle modifications including weight loss on the impact of neuropathic pain symptoms.CrossRefGoogle Scholar
  23. 23.
    Tin SNW, Zouari HG, Ayache SS, et al. Coaching of lifestyle recommendations improves sensory neurophysiological parameters in neuropathies related to glycemic disorder or metabolic syndrome. A pilot study. Neurophysiol Clin. 2019;49(1):59–67.  https://doi.org/10.1016/j.neucli.2018.12.004.CrossRefGoogle Scholar
  24. 24.
    Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10:93–102.  https://doi.org/10.1007/s11739-014-1157.CrossRefPubMedGoogle Scholar
  25. 25.
    Li G. Effect of mecobalamin on diabetic neuropathies. Beijing methycobal clinical trial collaborative group. Zhonghua Nei Ke Za Zhi. 1999;38(1):14–7.PubMedGoogle Scholar
  26. 26.•
    Sil A, Kumar H, Mondal RD, Anand SS, Ghosal A, Datta A, et al. A randomized, open labeled study comparing the serum levels of cobalamin after three doses of 500mcg vs a single dose methylcobalamin of 1500 mcgin patients with peripheral neuropathy. Korean J Pain. 2018;31(3):183–90.  https://doi.org/10.3344/kjp.2018.31.3.183. This paper compares the cellular uptake of Methylcobalamin (MC) and cobalamin in patients with peripheral neuropathy.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2013;101(2):99–105.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang M, Han W, Hu S, Xu H. Methylcobalamin: a potential vitamin of pain killer. Neural Plast. 2013;2013:424651, 6 pages.  https://doi.org/10.1155/2013/424651.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Jiang DQ, Li MX, Wang Y, Wang Y. Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: a meta-analysis. Neurosci Lett. 2015;594:23–9.  https://doi.org/10.1016/j.neulet.2015.03.037.CrossRefPubMedGoogle Scholar
  30. 30.
    Fonseca VA, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126(2):141–9.  https://doi.org/10.1016/j.amjmed.2012.06.022.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.•
    Mottaghi T, Khorvash F, Maracy M, Bellissimo N, Askari G. Effect of folic acid supplementation on nerve conduction velocity in diabetic polyneuropathy patients. Neurol Res. 2019;41(4):364–8.  https://doi.org/10.1080/01616412.2019.1565180. Results from this study show that folic acid supplementation for 16 weeks may be enhance nerve conduction velocity in patients with diabetic polyneuropathy.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabet Med. 2012;29(1):43–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med. 2008;168(7):771–2.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract. 2015;24(3):250–6.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4:e000148.  https://doi.org/10.1136/bmjdrc-2015-000148.CrossRefGoogle Scholar
  36. 36.
    De Leeuw I, Engelen W, De Block C, Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res. 2004;17(2):109–14.PubMedPubMedCentralGoogle Scholar
  37. 37.•
    Chu C, Zhao W, Zhang Y, Li L, Lu J, Jiang L, et al. Low serum magnesium levels are associated with impaired peripheral nerve function in type 2 diabetic patients. Sci Rep. 2016:32623.  https://doi.org/10.1038/srep32623. The study (n=978) explores the relationship between serum magnesium and peripheral nerve function in patients with type 2 diabetes, suggesting a correlation between magnesium levels and peripheral nerve function via axonal degeneration.
  38. 38.•
    Zhang Q, Ji L, Zheng H, Li Q, Ziong Q, Sun W, et al. Low serum phosphate and magnesium levels are associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:1–7.  https://doi.org/10.1016/j.diabres.2018.09.015. This study in patients with type 2 diabetes demonstrates a significant correlational relationship between lower serum phosphate and magnesium levels with various parameters of nerve conduction, suggesting the pathophysiological importance of serum phosphate and magnesium in DPN.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–60.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy. Free Radic Res. 1999;31(3):171–9.Google Scholar
  41. 41.••
    Agathos E, Tentolouris A, Eleftheriadou I, Katsaouni P, Nemtzas I, Petrou A, et al. Effect of a-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018;46(5):1779–90.  https://doi.org/10.1177/0300060518756540. This study investigates dose and clinical use of ALA in neuropathic pain.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    De Grandis D. Tolerability and efficacy of 1-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study. Clin Drug Invest. 1998;15:73–9.CrossRefGoogle Scholar
  44. 44.
    Youle M, Osio M. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007;8(4):241–50.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Li S, Li Q, Li Y, Li L, Tian H, Sun X. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(3):e0119479. ECollection 2015.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Anders AF, Sima MC, Munish M, Antonino A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005;28(1):89–94.  https://doi.org/10.2337/diacare.28.1.89.CrossRefGoogle Scholar
  47. 47.••
    Li S, Chen X, Li Q, Du J, Liu Z, Peng Y, et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016;7(5):777–85. A well-designed randomized trial comparing acetyl-L-carnitine with methylcobalamin and found benefit (noninferiority) with ALC.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16(12):1221–32.  https://doi.org/10.1016/j.jpain.2015.07.009.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    •• Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W, et al. Cochrane Database Syst Rev. 2018;3:CD012182.  https://doi.org/10.1002/14651858.CD012182.pub2. A thorough overviews of cannabis use and the pros and cons to its use in neuropathic pain.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Modesto-Lowe V, Bojka R, Alvarado C. Cannabis for peripheral neuropathy: the good, the bad, and the unknown. Cleve Clin J Med. 2018;85(12):943–9.  https://doi.org/10.3949/ccjm.85a.17115.CrossRefPubMedGoogle Scholar
  51. 51.
    Verhulst AL, Savelberg HH, Vreugdenhil G, Mischi M, Schep G. Whole-body vibration as a modality for the rehabilitation of peripheral neuropathies: implications for cancer survivors suffering from chemotherapy-induced peripheral neuropathy. Oncol Rev. 2015;9(1):263.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Lee K, Lee S, Song C. Whole-body vibration training improves balance, muscle strength and glycosylated hemoglobin in elderly patients with diabetic neuropathy. Tohoku J Exp Med. 2013;231(4):305–14.PubMedCrossRefGoogle Scholar
  53. 53.
    Kordi Yoosefinejad A, Shadmehr A, Olyaei G, Talebian S, Bagheri H, Mohajeri-Tehrani MR. Short-term effects of the whole-body vibration on the balance and muscle strength of type 2 diabetic patients with peripheral neuropathy: a quasi-randomized-controlled trial study. J Diabetes Metab Disord. 2015;14:4. eCollection 2015.Google Scholar
  54. 54.
    Chanou K, Gerodimos V, Karatrantou K, Jamurtas A. Whole-body vibration and rehabilitation of chronic diseases: a review of the literature. J Sports Sci Med. 2012;11(2):187–200.PubMedPubMedCentralGoogle Scholar
  55. 55.•
    Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, et al. A pilot randomized sham-controlled trial of MC5-a scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy. J Palliat Care. 2019:825859719827589.  https://doi.org/10.1177/0825859719827589. This study is a randomized sham-controlled Phase II trial of scrambler therapy in chemotherapy-induced peripheral neuropathy, demonstrating no difference between sham and real scrambler therapy.
  56. 56.
    Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, et al. Pilot evaluation of scrambler therapy for the treatment of chemotherapy induced peripheral neuropathy. Support Care Cancer. 2015;23(4):943–51.  https://doi.org/10.1007/s00520-014-2424-8.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Ricci M, Fabbri L, Pirotti S, Ruffilli N, Foca F, Maltoni M. Scrambler therapy: what’s new after 15 years? The results from 219 patients treated for chronic pain. Medicine (Baltimore). 2019;98(2):e13895.  https://doi.org/10.1097/MD.0000000000013895.CrossRefGoogle Scholar
  58. 58.
    Hegde SV, Adhikari P, Shetty S, Manjrekar P, D’Souza V. Effect of community-based yoga intervention on oxidative stress and glycemic parameters in prediabetes: a randomized controlled trial. Complement Ther Med. 2013;21(6):571–6.  https://doi.org/10.1016/j.ctim.2013.08.013.CrossRefPubMedGoogle Scholar
  59. 59.
    Hegde SV, Adhikari P, Kotian S, Pinto VJ, D’Souza S, D’Souza V. Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care. 2011;34(10):2208–10.  https://doi.org/10.2337/dc10-2430.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Malhotra V, Singh S, Tandon OP, Madhu SV, Prasad A, Sharma SB. Effect of yoga asanas on nerve conduction in type 2 diabetes. Indian J Physiol Pharmacol. 2002;46(3):298–306.PubMedGoogle Scholar
  61. 61.•
    Van Puymbroeck M, Atler K, Portz JD, Schmid AA. multidimensional improvements in health following hatha yoga for individuals with diabetic peripheral neuropathy. Int J Yoga Therap. 2018;28(1):71–8.  https://doi.org/10.17761/2018-00027. In patients with diabetic peripheral neuropathy completing an 8-week Hatha Yoga trial, it has been suggested that yoga can improve neuromuscular and movement-based functions, sensory functions, and stress management and sleep improvement via breathwork. In addition, participation, social support, and environmental factors may contribute to a holistic improvement of health.PubMedCrossRefGoogle Scholar
  62. 62.
    Zeidan F, Vago DR. Mindfulness meditation-based pain relief: a mechanistic account. Ann N Y Acad Sci. 2016;1373(1):114–27.  https://doi.org/10.1111/nyas.13153.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Tavee J, Rensel M, Planchon SM, Butler RS, Stone L. Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. Int J MS Care. 2011. Winter;13(4):163–8.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Teixeira E. The effect of mindfulness meditation on painful diabetic peripheral neuropathy in adults older than 50 years. Holist Nurs Pract. 2010;24(5):277–83.  https://doi.org/10.1097/HNP.0b013e3181f1add2.CrossRefPubMedGoogle Scholar
  65. 65.•
    Lim TK, Ma Y, Berger F, Litscher G. Acupuncture and neural mechanism in the management of low back pain-an update. Medicines (Basel). 2018;5(3):63. Published 2018.  https://doi.org/10.3390/medicines5030063. This review focuses on the analgesic effects of acupuncture on low back pain as well as the neurological mechanisms and incidence of low back pain globally.PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Ben-Horin I, Kahan P, Ryvo L, Inbar M, Lev-Ari S, Geva R. Acupuncture and reflexology for chemotherapy-induced peripheral neuropathy in breast cancer. Integr Cancer Ther. 2017;16(3):258–62.  https://doi.org/10.1177/1534735417690254.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    •• Dimitrova A, Murchison C, Oken B. Acupuncture for the treatment of peripheral neuropathy: a systematic review and meta-analysis. J Altern Complement Med. 2017;23(3):164–79.  https://doi.org/10.1089/acm.2016.0155 A succinct review of potential mechanisms and beneficial use of acupuncture in neuropathic pain.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.•
    Shin KM, Lee S, Lee EY, Kim CH, Kang JW, Lee CK, et al. Electroacupuncture for painful diabetic peripheral neuropathy: a multicenter, randomized, assessor-blinded, controlled trial. Diabetes Care. 2018;41(10):e141–2.  https://doi.org/10.2337/dc18-1254. The study explores the effectiveness and safety of electroacupuncture in the treatment of painful diabetic neuropathy (PDN) compared to placebo and usual care.
  69. 69.•
    Zhi WI, Ingram E, Li SQ, Chen P, Piulson L, Bao T. Acupuncture for bortezomib-induced peripheral neuropathy: not just for pain. Integr Cancer Ther. 2018;17(4):1079–86.  https://doi.org/10.1177/1534735418788667. This study examines the safety and efficacy of acupuncture in Bortezomib-induced peripheral neuropathy (BIPN), demonstrating that acupuncture can decrease total neuropathic symptoms, especially cold sensitivity and numbness and tingling in hands and feet.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.•
    Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, et al. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. Eur J Cancer. 2018;101:12–9.  https://doi.org/10.1016/j.ejca.2018.06.008. This study in chemotherapy-induced peripheral neuropathy showed acupuncture to be was safe and effective in reducing the incidence of high grade CIPN during chemotherapy.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Hashempur MH, Homayouni K, Ashraf A, Salehi A, Taghizadeh M, Heydari M. Effect of Linum usitatissimum L. (linseed) oil on mild and moderate carpal tunnel syndrome: a randomized, double-blind, placebo-controlled clinical trial. Daru. 2014;22:43.  https://doi.org/10.1186/2008-2231-22-43.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.•
    Hashempur MH, Ghasemi MS, Daneshfard B, Fhoreishi PS, Lari ZN, Homayouni K, et al. Efficacy of topical chamomile oil for mild and moderate carpal tunnel syndrome: a randomized double-blind placebo-controlled clinical trial. Complement Ther Clin Pract. 2017;26:61–7.  https://doi.org/10.1016/j.ctcp.2016.11.010. This study evaluates the efficacy of topical chamomile oil as a complementary treatment in patients with mild and moderate carpal tunnel syndrome (CTS) as measured through functional and symptomatic scores, dynamometry, and electrodiagnostic indexes.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Bellampalli SS, Ji Y, Moutal A, Cai S, Wijeratne EMK, Gandini MA, et al. Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels. Pain. 2019;160(1):117–35.  https://doi.org/10.1097/j.pain.0000000000001385.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.•
    Castelli V, Palumbo P, d’Angelo M, Moorthy NK, Antonosante A, Catanesi M, et al. Probiotic DSF counteracts chemotherapy induced neuropathic pain. Oncotarget. 2018;9(46):27998–8008.  https://doi.org/10.18632/oncotarget.25524. This study test the effects of probiotics on counteracting paclitaxel-induced neuropathic pain since probiotics are capable of regulating the anti-inflammatory and pro-inflammatory cytokines. The study resulted in an increase in acetylated tubulin.
  75. 75•.
    Youn Y, Hellman A, Walling I, Gee L, Qian J, Burdette C, et al. High-intensity ultrasound treatment for vincristine-induced neuropathic pain. Neurosurgery. 2018;83(5):1068–75.  https://doi.org/10.1093/neuros/nyx488. This study determining the effects of pulsed high-intensity focused ultrasound (HIFU) on sensory thresholds in a vincristine-induced neuropathy (VIN) rodent model, resulting in increases mechanical and thermal thresholds.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.•
    Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, et al. The long-term impact of neurofeedback on symptom burden and interference in patients with chronic chemotherapy-induced neuropathy: analysis of a randomized controlled trial. J Pain Symptom Manag. 2018;55(5):1276–85.  https://doi.org/10.1016/j.jpainsymman.2018.01.010. This study on the long-term effects of electroencephalographic neurofeedback (NFB) as a treatment for chemotherapy-induced peripheral neuropathy (CIPN) in 71 cancer survivors demonstrates that NFB results in CIPN symptom reductions and improved quality of life and fatigue.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Vanessa Baute
    • 1
    Email author
  • Danielle Zelnik
    • 1
    • 2
  • Jarret Curtis
    • 1
  • Fatemeh Sadeghifar
    • 1
  1. 1.Department of NeurologyWake Forest School of MedicineWinston SalemUSA
  2. 2.Integrative Medicine CenterConcentraOklahoma CityUSA

Personalised recommendations